News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hyperion Therapeutics Announces The Publication Of Phase 2 Results Of Glycerol Phenylbutyrate (GPB) For The Treatment Of Hepatic Encephalopathy In Hepatology


2/25/2014 9:06:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRISBANE, Calif., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the March 2014 issue of Hepatology. The study met its primary endpoint with significantly fewer patients treated with GPB experiencing HE events as compared to patients receiving placebo.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES